Premium
Chromosome changes and splenectomy in Ph 1 ‐positive chronic myeloid leukemia: I. Predictive parameters in the blastic phase
Author(s) -
Sadamori Naoki,
Sandberg Avery A.
Publication year - 1984
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19841201)54:11<2456::aid-cncr2820541124>3.0.co;2-6
Subject(s) - splenectomy , medicine , clone (java method) , myeloid leukemia , philadelphia chromosome , gastroenterology , bone marrow , chromosome , myeloid , immunology , spleen , pathology , oncology , biology , genetics , dna , gene , chromosomal translocation
The effects of splenectomy in the blastic phase (BP) of Philadelphia (Ph 1 )‐positive chronic myeloid leukemia (CML) were correlated with the chromosome findings at the BP. The 53 patients studied were divided into four groups on the basis of the chromosome findings in the bone marrow and/or blood and whether splenectomy was performed after the onset of the BP, i.e. , patients with only a Ph 1 clone with or without splenectomy and those with abnormal clones containing karyotypic abnormalities in addition to Ph 1 with or without splenectomy. Statistical analyses showed that splenectomy for patients with abnormal clones in addition to Ph 1 at the BP affected positively both median survival and percentage of patients with a good therapeutic response and that splenectomy in patients with only a Ph 1 clone contributed to an improvement in the tolerance to chemotherapy.